Zacks Investment Research
15 Jan 2026, 15:16 UTC · 42w ago
Verdict
Headline takes no side. We score KROS +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
What the story claims
4 claims · scored −1 bearish … +1 bullish
Keros Therapeutics entered into an exclusive license agreement with Takeda Pharmaceuticals for the development and commercialization of elritercept worldwide (excluding China, Hong Kong, and Macau).
More positive than 93% of claims this week
Keros Therapeutics received FDA orphan drug designation for its lead product candidate, KER-065, for the treatment of Duchenne muscular dystrophy (DMD).
Continue reading
5 related stories
More positive than 76% of claims this week
Keros Therapeutics plans to begin a phase II trial for KER-065 in patients with DMD in the first quarter of 2026.
More positive than 63% of claims this week
Keros Therapeutics initiated a strategic review aimed at maximizing stockholder value.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company has seen shares skyrocket 85.6%, outperforming the sector and S&P 500 with encouraging pipeline progress.
More positive than 56% of ticker scores this week
Entered into an exclusive license agreement to develop and commercialize elritercept.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
3h ago
−51.2%
Price is moving against the score
$9.54 vs $19.53 close before publication (Jan 14) · not market-adjusted
KROS chart →
